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Treat Sustained Ventricular
Tachycardia in Patients
With Chagas Cardiomyopathy
and Implantable
Cardioverter-DeﬁbrillatorWe have read with great interest the recent paper by Nunes et al.
(1). We congratulate the authors for this comprehensive review of
Chagas cardiomyopathy, which is one of the most important car-
diovascular problems in Latin America and also an emerging dis-
ease in nonendemic countries.
As the authors properly described, ventricular arrhythmias are
very common in patients with Chagas heart disease, with preva-
lence and complexity related to the presence and extent of
myocardial damage. Sustained rapid ventricular tachycardia (VT) isrecognized as the most important cause of sudden cardiac death in
Chagas disease. It has been identiﬁed in patients with a segmental
disease, with or without important ventricular dysfunction,
and the implantable cardioverter-deﬁbrillator (ICD) has been rec-
ommended for those patients to prevent sudden cardiac death.
However, some observations suggest that patients with Chagas
disease receive more ICD shocks when compared with patients
with other structural heart diseases (2,3). As previously shown (4),
frequent ICD shocks are associated with higher mortality in pa-
tients with low ejection fraction of any etiology. So, it is not sur-
prising that a similar observation applies to patients with Chagas
VT and frequent ICD discharges that have shown a high total
mortality rate when their deﬁbrillators are conventionally pro-
grammed (5,6).
It is important to mention that catheter ablation is currently
recommended to manage patients with incessant or recurrent
VTs, mainly when receiving frequent ICD therapies (7). In
treating hundreds of patients with these characteristics, we were
able to deﬁne the substrate of most of these VTs: most re-entrant
circuits in Chagas VTs originate in the inferior or lateral basal
wall of the left ventricle. Moreover, after developing the tech-
nique of subxiphoid percutaneous access to the pericardial space
in our laboratory, we were able to identify that subepicardial
myocardial ﬁbers were the cause for re-entrant circuits of sus-
tained VT in many patients with Chagas disease (8,9). This
ﬁnding has allowed us to successfully ablate VT for patients with
prior endocardial ablation failures (10). These observations have
been largely conﬁrmed in the literature, and are currently rec-
ommended for managing speciﬁc patients with recurrent VTs,
particularly those with Chagas VT and other nonischemic car-
diomyopathies (11,12).
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Sustained Ventricular
Tachycardia in Patients With
Chagas Cardiomyopathy and
Implantable Cardioverter-DeﬁbrillatorWe would like to thank Drs. Scanavacca and Sosa for their letter
regarding our review (1), which outlined an important aspect
related to the management of patients with Chagas heart disease
(CHD) and malignant arrhythmias. Patients with CHD have a
higher risk of death than idiopathic dilated cardiomyopathy (2),
possibly related to the higher frequency and severity of ventricular
arrhythmia in CHD subjects when compared with other structural
heart diseases (3,4). The higher number of shocks observed in
CHD patients is related to the higher incidence of ventricular
tachycardia (VT) and ﬁbrillation in implantable cardioverter-
deﬁbrillator (ICD) patients (4) and to the higher risk of death (5).
Amiodarone, which has been largely used in CHD (6), in association
with beta-blockers, may prevent shocks in ICD patients but not in
all patients, and only at the cost of an increased risk of drug-related
adverse effects (7). As Dr. Scanavacca and Dr. Sosa correctly
point out, ablation therapy emerges as the ﬁrst-line treatment for
those receiving frequent ICD therapies due to incessant and recur-
rent VT in spite of amiodarone and beta-blocker therapy in CHD.However, several aspects of this treatment option in CHD
should be better elucidated. Dr. Scanavacca and Dr. Sosa’s group
have to be praised for the introduction of the technique of
nonsurgical transthoracic epicardial catheter ablation to treat
recurrent VT in CHD patients (8), which is now used for VT
ablation of other etiologies (9). CHD patients frequently have
epicardial VT breakthroughs (8,10) and a combined epicardial/
endocardial substrate mapping, and ablation has been proposed as a
ﬁrst-line therapy for preventing VT recurrences and appropriate
ICD therapies (8,10). Indeed, the use of extended substrate
modiﬁcation in patients with ischemic cardiomyopathydwith
routine approach to endocardial and epicardial surfacedwas more
effective in preventing VT recurrences than the limited (traditional)
substrate ablation (9). This is a hypothesis that deserves to be tested
in CHD in a prospective, randomized trial.
CHD is now a global health problem, but most infected patients
are poor people born in rural, endemic areas in Latin America;
thus, few randomized studies have been performed for treatment of
CHD complications (11,12). Globalization of knowledge and
evidence-based medicine should be matched by attempts to provide
solutions for regional and neglected pathologies in addition to
global health problems (13).Maria Carmo Pereira Nunes, MD, PhD
Andre Assis L. Carmo, MD
Wistremundo Dones, MD
Carlos A. Morillo, MD
Juan Justiniano Encina, MD
*Antonio Luiz Ribeiro, MD, PhD
On behalf of the Council on Chagas Disease
of the Interamerican Society of Cardiology
*Departamento de Clínica Médica
Faculdade de Medicina da Universidade Federal de Minas Gerais
Avenida Professor Alfredo Balena, 190, Santa Eﬁgênia
30130 100–Belo Horizonte, MG
Brazil
E-mail: tom@hc.ufmg.br
http://dx.doi.org/10.1016/j.jacc.2013.11.033
REFERENCES
1. Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL, for the
Council on Chagas Disease of the Interamerican Society of Cardiology.
Chagas disease: an overview of clinical and epidemiological aspects.
J Am Coll Cardiol 2013;62:767–76.
2. Nunes MD, Barbosa MM, Ribeiro AL, Amorim Fenelon LM,
Rocha MO. Predictors of mortality in patients with dilated cardio-
myopathy: relevance of Chagas disease as an etiological factor. Rev Esp
Cardiol 2010;63:788–97.
3. Rincon LG, Rocha MO, Pires MT, et al. [Clinical proﬁle of Chagas
and non-Chagas’ disease patients with cardiac pacemaker]. Rev Soc
Bras Med Trop 2006;39:245–9.
4. Barbosa MP, da Costa Rocha MO, de Oliveira AB, Lombardi F,
Ribeiro AL. Efﬁcacy and safety of implantable cardioverter-deﬁbrillators
in patients with Chagas disease. Europace 2013;15:957–62.
5. Cardinalli-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Pre-
dictors of all-cause mortality for patients with chronic Chagas’ heart
disease receiving implantable cardioverter deﬁbrillator therapy.
J Cardiovasc Electrophysiol 2007;18:1236–40.
6. Scanavacca MI, Sosa EA, Lee JH, Bellotti G, Pileggi F. [Empiric
therapy with amiodarone in patients with chronic Chagas cardiomy-
opathy and sustained ventricular tachycardia]. Arq Bras Cardiol 1990;
54:367–71.
